Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies (BEST) . The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
Last trade$61.54
Day change+$0.915 (+1.51%)
Day range$60.09 – $62.06
Volume862,800
Market cap$9.26B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$9.26B
Price / earnings
—
Price / book
4.01×
Price / sales
2.64×
EV / sales
3.09×
EV / EBITDA
23.18×
Profitability
Earnings per share
-$1.10
Return on assets
-2.87%
Return on equity
-7.25%
Dividend yield
0.79%
Liquidity and leverage
Debt / equity
0.74×
Current ratio
1.84×
Quick ratio
0.9×
Cash ratio
0.1×
Cash flow
Price / cash flow
27.09×
Price / free cash flow
43×
Free cash flow
$215.3M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for BRKR, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$874M
$838.5M
$823.4M
$977.2M
$860.5M
$797.4M
$801.4M
$979.6M
Cost of revenue
$444.7M
$422.5M
$443.6M
$528M
$481.1M
$439.5M
$410.2M
$486.3M
Gross profit
$429.3M
$416M
$379.8M
$449.2M
$379.4M
$357.9M
$391.2M
$493.3M
Selling, general and administrative
$226.5M
$238.9M
$242.1M
$247.2M
$242.5M
$231.4M
$225.4M
$247.3M
Research and development
$92M
$94.3M
$101.3M
$99.6M
$98.3M
$100.2M
$97.1M
$104.4M
Total operating expenses
$520.3M
$481.3M
$369.6M
$372.9M
$431.2M
$346M
$359.4M
$421.2M
Operating income
-$91M
-$65.3M
$10.2M
$76.3M
-$51.8M
$11.9M
$31.8M
$72.1M
Interest expense
-$15.4M
-$17.8M
$0
$0
-$20.3M
-$15.7M
$0
$0
Income before taxes
-$120.3M
-$40.7M
$21.9M
$68.2M
-$71.8M
$500K
$25.1M
$56.1M
Income taxes
-$12.2M
$14.2M
$2.5M
$37.8M
-$14.1M
-$3.1M
$8.7M
$40.7M
Net income
-$109.7M
-$50.9M
$15.7M
$29.2M
-$58.5M
$4.2M
$16.8M
$13.9M
Net income attributable to common shareholders
-$122.8M
-$62.9M
$3.5M
$14.9M
-$62.4M
$7.6M
$17.4M
$13.7M
EBITDA
$137.6M
$127.6M
$68.5M
$134.4M
$100.4M
$68M
$82.2M
$125M
Basic earnings per share
-$0.81
-$0.41
$0.02
$0.10
-$0.41
$0.05
$0.11
$0.09
Diluted earnings per share
-$0.81
-$0.41
$0.02
$0.10
-$0.41
$0.05
$0.11
$0.09
Recent news
Company coverage with links to the original publishers.
Bruker Corporation (BRKR), a life science and materials research systems manufacturer, is highlighted as a momentum investment opportunity despite holding a #3 (Hold) Zacks Rank. The stock has gained 9.5% over four weeks with positive earnings estimate revisions and a strong Momentum Style Score of A, though it carries a VGM Score of B.
Bruker Corporation (BRKR) is well-positioned for growth driven by strong diagnostics and biosystems revenue, favorable European demand, and a $140 million cost-savings target by 2026 aimed at expanding margins by 250-300 basis points. However, uneven U.S. academic demand, macroeconomic uncertainty, and trade policy volatility present headwinds. The stock carries a Zacks Rank #3 (Hold) rating with a 3.4% earnings yield.
Bruker Corporation (BRKR) shares gained 66.3% over the past year, driven by strong demand in biopharma, diagnostics, and mass spectrometry. However, the company faces a $134.9M goodwill impairment, currency headwinds, and restructuring costs. Full-year 2026 revenue guidance was lowered to $3.54-$3.57B due to currency pressures, though the company maintains a solid financial position with $184.9M in cash.
Bruker Corporation (BRKR) is experiencing elevated implied volatility in its December 2026 $75 put options, suggesting traders expect significant price movement. However, the fundamental outlook remains weak, with analysts downgrading estimates over the past 60 days, pushing the consensus estimate down from 55 cents to 42 cents per share. The stock holds a Zacks Rank #3 (Hold) rating.
Bruker Corporation (BRKR), a life science and materials research systems manufacturer, is highlighted as a momentum investment opportunity despite holding a #3 (Hold) Zacks Rank. The stock has gained 4.3% over the past four weeks and features strong Momentum and VGM Style Scores of A and B respectively. One analyst raised earnings estimates for fiscal 2026, with the consensus estimate at $2.12 per share and an average earnings surprise of +22.7%.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Sep 21, 2026
$0.05
Oct 7, 2026
recurring
Jun 22, 2026
$0.05
Jul 7, 2026
recurring
Mar 23, 2026
$0.05
Apr 7, 2026
recurring
Dec 8, 2025
$0.05
Jan 2, 2026
recurring
Sep 23, 2025
$0.05
Oct 3, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.